Side-by-side · Research reference

PancragenvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Pancragen

VIP

Primary target

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Yes — preserves physiological glucose-insulin response

Yes — exogenous VIP acts as physiological agonist

Origin

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Pancragen

VIP

Primate dose (rhesus macaque)

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

—

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

—

Route

IntramuscularGoncharova 2015

—

Frequency

Once daily for 10 daysGoncharova 2014

—

Treatment cycle

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

—

Evidence basis

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Diabetes model

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

—

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

04Side Effects & Safety

Parameter

Pancragen

VIP

Reported adverse events

None documented in primate studies

—

Tolerability

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

—

Human safety data

No published human trials; clinical use limited to Russian gerontology protocols

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Pancragen

—

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Pancragen

VIP

1. Reconstitution

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Route

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

No specific timing constraints documented. Administered once daily in primate protocols.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Cycle structure

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.